2[3]White MH,Anaissie EJ,Kusne S,et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis, 1997,24:635 ～ 642 被引量：1
3[4]Johnson HB, Kaeffmen CA. Voriconazole: An ewtriazole antifungalagent. Clin Infect Dis,2003,36:610 ～617 被引量：1
4[5]Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J AntimicrobAgents ,2001,18:167 ～ 172 被引量：1
5[6]Arikan S,Rex JH. New agents for the treatment of systemic fungal infections - current status. Expert Opin Emerging Drugs,2002, 7:241 ～ 244 被引量：1
6[7]Lefscher BV,Herbrecht R. Caspofungin:the first representative of an new antifungal class. J Antimicrob Chemother,2003,51:513 ～521 被引量：1
8[9]Uzun O,Kocagoz S, Cetinkaya Y, et al. Invitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother, 1997,41:1156 ～ 1157 被引量：1
